Humira Drug Market 2024 - By Growth Rate, Sales, Production, Consumption Manufacturers, Shares And Outlook By 2033

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Humira Drug Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $13.05 billion In 2028 At A CAGR Of 7.3%.

The humira drug market size has grown strongly in recent years. It will grow from $9.19 billion in 2023 to $9.86 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to introduction of biologics, biotechnology advancements, patient demand for effective treatments, physician adoption and prescribing patterns.

The humira drug market size is expected to see strong growth in the next few years. It will grow to $13.05 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to biosimilar market entry, healthcare policy changes, focus on cost-effectiveness, research and development investments, precision medicine and personalized treatments. Major trends in the forecast period include real-world evidence generation, expanded use in pediatric populations, shift towards self-administered medications, value-based pricing models, targeted therapies development.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=11934&type=smp

Humira Drug Market Major Segments
The humira drug market covered in this report is segmented -

1) By Type: Humira Syringe, Humira Pen
2) By Application: Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn's Disease, Other Applications
3) By End-Users: Hospitals, Specialty Clinics, Other End-Users

Key Driver - Growing Incidence Of Autoimmune Diseases Fuels Demand For Humira Drug

A rise in the incidence rate of autoimmune disease is expected to propel the growth of the humira drug market going forward. Autoimmune disease refers to a type of disease in which the body's immune system attacks and destroys healthy tissues and cells in the body. Humira drug is used to treat pain and inflammation caused by various autoimmune diseases, as a result, the rise in the incidence rate of autoimmune diseases increases the demand for humira drug. For instance, in July 2021, according to Cleveland Clinics, a US-based non-profit academic medical center, 1 in 15 people in the U.S. have an autoimmune disease. Further, one million people in the U.S. are suffering from lupus and 1.4 million have Crohn's disease or ulcerative colitis respectively. Therefore, the rise in the incidence rate of autoimmune disease will drive the HUMIRA drug market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=11934&type=smp

Prominent Trend - Innovative Formulations Drive Advancements In Humira Drug Market

Product innovations are a key trend in the humira drug market. Major companies in the humira drug market are developing new biologics and biosimilars to sustain their position in the market. For instance, in April 2023, Sandoz, a Switzerland-based pharmaceutical company introduced Biosimilar Hyrimoz (adalimumab), a citrate-free high-concentration formulation (HCF) approved by the European Commission. The adalimumab citrate-free HCF (100 mg/mL) formulation provides a 50 % reduction in injection volume and decreases the number of injections required for patients opting for 80 mg/mL or higher dosing. This is applicable to various diseases such as rheumatic diseases, Crohn's disease, and others with enhanced familiar experience.

Humira Drug Market Players
Major companies operating in the humira drug market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Fresenius Kabi AG, Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sandoz International GmbH, Hikma Pharmaceuticals PLC, Celltrion Healthcare Co. Ltd., Cadila Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Mochida Pharmaceutical Co. Ltd., Innovent Biologics Inc., Biocad Biopharmaceutical Company, Shanghai Henlius Biotech Inc., Glenmark Pharmaceuticals Ltd., Samsung Bioepis Co Ltd., Hetero Healthcare Ltd., Coherus BioSciences Inc., CinnaGen Co., Alvotech Holdings S.A, Reliance Life Sciences Private Limited, Momenta Pharmaceuticals Inc., Bio-Thera Solutions Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., BioXpress Therapeutics SA, Alteogen Inc., Prestige BioPharma Pte. Ltd.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/humira-drug-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the humira drug market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the humira drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Humira Drug Market Report Structure
3. Humira Drug Market Trends And Strategies
4. Humira Drug Market - Macro Economic Scenario
5. Humira Drug Market Size And Growth
…..
27. Humira Drug Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.